Officially Named
HM71224, a new autoimmune treatment developed by Hanmi Pharmaceutical, was assigned an official generic name of Poseltinib.
Hanmi Pharmaceutical announced on March 7 that its autoimmune disease treatment candidate has been recently registered in the name of Poseltinib in the International Non-proprietary Name (INN) assigned by the World Health Organization. An INN identifies a pharmaceutical substance or active pharmaceutical ingredient by a unique name to make easy to remember.
Poseltinib is a substance licensed out to Eli Lilly, a U.S.-based global pharmaceutical company, in March 2015. It is a novel immune treatment that selectively inhibits Bruton’s tyrosine kinase (BTK) that plays a crucial role in B-cell development in the body.
Poseltinib is being developed to treat various diseases such as lupus, nephritis and Sjogren’s syndrome. It is currently undergoing global phase 2 clinical trials on patients with rheumatoid arthritis initiated by Eli Lilly.
An official from Hanmi Pharmaceutical said, “We will put utmost efforts with our partner Eli Lilly for successful commercialization of Poseltinib.”